Safety Extension Study of Edaravone Oral Suspension in Patients With Amyotrophic Lateral Sclerosis for up to an Additional 96 Weeks of Treatment
一项针对肌萎缩侧索硬化症患者的依达拉奉口服混悬液安全性扩展研究,疗程最长可达96周
期刊:Muscle & Nerve
影响因子:3.1
doi:10.1002/mus.28451
Genge, Angela; Pattee, Gary L; Sobue, Gen; Aoki, Masashi; Yoshino, Hiide; Couratier, Philippe; Lunetta, Christian; Petri, Susanne; Selness, Daniel; Todorovic, Vesna; Sasson, Nissim; Hirai, Manabu; Takahashi, Fumihiro; Salah, Alejandro; Apple, Stephen; Wamil, Art; Kalin, Alexander; Jackson, Carlayne E